Assembly Biosciences Inc (ASMB) Q1 2019 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q1 2019 10-Q quarterly report on May 9, 2019 for the quarter ended Mar 31, 2019.

AI summary of MD&A and risk factor updates

Collaboration revenue $3.9M, up from $3.6M YoY, despite decreased Allergan activities and reimbursements
Net loss $27.1M vs $16.2M YoY, with R&D expense $22.7M vs $14.5M
HBV-cure R&D increased $6.4M, outperforming Microbiome program increase of $1.6M
Operating cash used $23.9M vs $15.5M YoY, with $11.4M investing cash provided
Final six-month ABI-H0731 data expected Q4 2019, ABI-H2158 data Q1 2020, ABI-H3733 Phase 1a expected Q1 2020

No material changes identified: filing presents carried-forward risks without quarter-specific additions or updates
Regulatory approval risk: no NDA or BLA submitted, leaving all candidates dependent on future FDA authorization
Clinical development risk: early-stage programs face high failure risk, with later trials potentially contradicting earlier results
Liquidity risk: current resources expected to fund operations at least 12 months, but additional financing remains necessary
Collaboration concentration risk: Allergan may terminate its agreement with 90 or 120 days’ notice, depending on trial timing

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.